Bharat Biotech International Limited a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced that iNCOVACC® (BBV154), has received approval from the Central Drugs Standard Control Organisation (CDSCO) under Rcstrictcd Use in Emcrgcncy Situation for ages 18 and above, in India, for heterologous booster doses.
source https://www.pharmatutor.org/pharma-news/2022/bharat-biotech-intranasal-vaccine-receives-cdsco-nod-for-booster
No comments:
Post a Comment